Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities
Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
To the best of the knowledge of Principal Investigators, there was no local study done to
assess the potential cognitive improvement seen with Vortioxetine when used as directed for
the treatment of Major Depressive Disorders. As such the outcome of this trial will provide
evidence to assess this claim in the Pakistani population. This would be the first randomized
trial dedicated for this assessment in the region with an active control of one of the most
commonly used Selective Serotonin and Norepinephrine Reuptake Inhibitors (SSNRIs) in Pakistan
for the treatment of depression, Venlafaxine. It can be utilized as an alternative to MDD
treatment options, especially where the focus is on improving the cognitive abilities of the
patients.